Compare J M Smucker Co (SJM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs Twist Bioscience Corp — how do they compare? J M Smucker Co trades at $119.83 (market cap $12.76B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: J M Smucker Co is the larger of the two by market cap, and J M Smucker Co pays a 3.75% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold J M Smucker Co for 74 Days and Twist Bioscience Corp for 27 Days on average.
| SJM | TWST | |
|---|---|---|
Market Cap | $12.76B | $10.08B |
Volume | 1,300,545 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $132.34 | $205.00 |
52-Week Low | $89.53 | $25.45 |
Typical Hold Time | 74 Days | 27 Days |
Enterprise Value | $19.61B | $10.01B |
Dividend Yield | 3.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM stock trades at $119.41, up 3.0% with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The company maintains strong cash flow from operations at $1.21B and recently raised FY27 EPS guidance to $10.50-$11.00. However, 2025 results showed a net loss of $1.23B despite $8.73B revenue, with elevated P/E ratio of 55.8 suggesting premium valuation.
Outlook remains cautiously optimistic with analyst consensus target of $138.23 (16% upside) and 52% buy ratings, though high debt levels and margin pressures present risks. The stock offers dividend income with upcoming $1.12 payment, while technical support at $118 provides near-term stability.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
